Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?-Reference-Cited by-同舟云学术

Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?

Published:2021-08-01 Issue:8 Volume:35 Page:327-334
ISSN:1087-2914
Container-title:AIDS Patient Care and STDs
language:en
Short-container-title:AIDS Patient Care and STDs

Author:

D'Angelo Alexa B.¹²^ORCID,Westmoreland Drew A.²,Carneiro Pedro B.¹^ORCID,Johnson Jeremiah³,Grov Christian¹²

Affiliation:

1. CUNY Graduate School of Public Health and Health Policy, New York, New York, USA.

2. CUNY Institute for Implementation Science in Population Health, New York, New York, USA.

3. Treatment Action Group, New York, New York, USA.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/apc.2021.0033

Reference36 articles.

1. 1. CDC. US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 Update: A Clinical Practice Guideline. Atlanta, GA: U.S. Department of Health and Human Services, 2018.

2. FDA paves the way for pre-exposure HIV prophylaxis

3. 7. Hare C, Coll J, Ruane P, et al. The phase 3 DISCOVER study: Daily F/TAF or F/TDF for HIV preexposure prophylaxis. In: Paper presented at: Conference on retroviruses and opportunistic infections, Seattle, Washington, March 4–7, 2019.

4. 8. Spinner C, Brunetta J, Shalit P, et al. DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF. In: Paper presented at: The International AIDS Conference, Mexico City, Mexico, July 21–24, 2019.

5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial;AIDS and Behavior;2024-09-02

2. Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States;Qualitative Health Research;2024-08-02

3. The landscape of small-molecule prodrugs;Nature Reviews Drug Discovery;2024-04-02

4. Evaluating effective interventions for the provision of PrEP for Black women: A systematic review (Preprint);2024-03-12

5. HIV Pre-Exposure Prophylaxis Uptake Among High-Risk Population in Sub-Saharan Africa: A Systematic Review and Meta-Analysis;AIDS Patient Care and STDs;2024-02-01